medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 3

<< Back Next >>

Ann Hepatol 2016; 15 (3)

Liver fibrosis in bile duct-ligated rats correlates with increased hepatic IL-17 and TGF-β2 expression

Zepeda-Morales ASM, Del Toro-Arreola S, García-Benavides L, Bastidas-Ramírez BE, Fafutis-Morris M, Pereira-Suárez AL, Bueno-Topete MR

Language: English
References: 37
Page: 418-426
PDF size: 262.99 Kb.


ABSTRACT

Background and rationale for the study. IL-17, TGF-β1/2 are cytokines involved in the development of kidney, pulmonary and liver fibrosis. However, their expression kinetics in the pathogenesis of cholestatic liver fibrosis have not yet been fully explored. The aim of the study was to analyze the expression of IL-17, RORγt, NKp46, TGF-β1, and TGF-β2 in the liver of rats with bile duct ligation (BDL). Results. Hepatic IL-17A gene expression analyzed by qRT-PCR showed a dramatic increase of 350 and 10 fold, at 8 and 30 days post BDL, respectively. TGFβ1 and TGFβ2 gene expression significantly increased throughout the whole fibrotic process. At the protein level in liver homogenates, IL-17, TGF-β1, and RORγt significantly increased at 8 and 30 days after BDL. Interestingly, a significant increase in the protein levels of TGF-β2 and decrease of NKp46 was observed only 30 days after BDL. Unexpectedly, TGF-β2 exhibited stronger signals than TGF-β1 at the gene expression and protein levels. Histological analysis showed bile duct proliferation and collagen deposition. Conclusions. Our results suggest that pro-fibrogenic cytokines IL-17, TGF-β1 and, strikingly, TGF-β2 might be important players of liver damage in the pathogenesis of early and advanced experimental cholestatic fibrosis. Th17 cells might represent an important source of IL-17, while NK cell depletion may account for the perpetuation of liver damage in the BDL model.


REFERENCES

  1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.

  2. Seki E, De Minicis S, Österreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF, et al. TLR4 enhances TGF- β signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32.

  3. Inagaki Y, Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007; 56: 284-92.

  4. Ferguson MWJ, O’Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 2004; 359: 839-50.

  5. Ferguson MWJ, Foreman, David M, Shah, Mamta. Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108: 985-102.

  6. Durani P, Occleston N, O’Kane S, Ferguson MWJ. Avotermin: a novel antiscarring agent. Int J Low Extrem Wounds 2008; 7: 160-8.

  7. Lee S-Y, Chuang J-H, Huang C-C, Chou M-H, Wu C-L, Chen C-M, Hdich, et al. Identification of transforming growth factors actively transcribed during the progress of liver fibrosis in biliary atresia. J Pediatr Surg 2004; 39: 702-8.

  8. Santos RM, Norton P, Degli Esposti S, Zern MA. TGF-beta isoforms in alcoholic liver disease. J Gastroenterol 1998; 33: 383-9.

  9. Zode GS, Sethi A, Brun-Zinkernagel A-M, Chang I-F, Clark AF, Wordinger RJ. Transforming growth factor-β2 increases extracellular matrix proteins in optic nerve head cells via activation of the Smad signaling pathway. Mol Vis 2011; 17: 1745-58.

  10. Gasse P, Riteau N, Vacher R, Michel M-L, Fautrel A, di Padova F, Fick L, et al. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PloS One 2011; 6: e23185.

  11. Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, Wang X, et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol 2013; 191: 1835-44.

  12. Nakashima T, Jinnin M, Yamane K, Honda N, Kajihara I, Makino T, Masuguchi S, et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012; 188: 3573-83.

  13. Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, Tocker J, et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006; 177: 36-9.

  14. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226: 57-79.

  15. Ge J, Wang K, Meng Q-H, Qi Z-X, Meng F-L, Fan Y-C. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol 2010; 30: 60-7.

  16. Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatol 2009; 49: 646-57.

  17. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, et al. IL-17 signaling in inflammatory cells, Kupffer cells and Hepatic Stellate cells exacerbates liver fibrosis. Gastroenterology 2012; 143: 765-76.

  18. Hara M, Kono H, Furuya S, Hirayama K, Tsuchiya M, Fujii H. Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice. J Surg Res 2013; 183(2): 574-82.

  19. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-89.

  20. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, et al. Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis. Annu Rev Immunol 2001; 19: 197-223.

  21. Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol 1986; 251: 176-80.

  22. De Aluja AS. Laboratory animals and official Mexican norms (NOM-062-ZOO-1999). Gac Médica México 2002; 138: 295-8.

  23. Mappes TA DD. Biomedical ethics. 6th ed. Boston: McGraw-Hill; 2006.

  24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.

  25. Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009; 157: 261-70.

  26. Jeong W-I, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatol Baltim Md 2006;44: 1441-51.

  27. Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatol 2013; 57: 1654-62.

  28. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8.

  29. Yu L, Border WA, Huang Y, Noble NA. TGF-beta isoforms in renal fibrogenesis. Kidney Int 2003; 64: 844-56.

  30. Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 2001; 170: 647-51.

  31. Wells RG. Cellular sources of extracellular matrix in hepatic fibrosis. Clin Liver Dis 2008; 12: 759-68.

  32. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, Witck R, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008; 118: 3331-42.

  33. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, Jones DEJ, et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Investig J Tech Methods Pathol 2008; 88: 112-23.

  34. Sato Y, Harada K, Ozaki S, Furubo S, Kizawa K, Sanzen T, Yasoshima M, et al. Cholangiocytes with mesenchymal features contribute to progressive hepatic fibrosis of the polycystic kidney rat. Am J Pathol 2007; 171: 1859-71.

  35. Kaimori A, Potter J, Kaimori J-Y, Wang C, Mezey E, Koteish A. Transforming growth factor-beta1 induces an epithelialto- mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 2007; 282: 22089-101.

  36. Xia J-L, Dai C, Michalopoulos GK, Liu Y. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol 2006; 168: 1500-12.

  37. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Lalluri R, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282: 23337-47.




2020     |     www.medigraphic.com